^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + lisaftoclax (APG-2575) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
APG-2575, a clinical stage BCL-2 selective inhibitor, sensitizes estrogen receptor-positive breast cancers to standard therapies in the preclinical models
Published date:
05/15/2020
Excerpt:
In a patient-derived, tamoxifen-resistant, ER+ breast cancer xenograft model, APG-2575 plus palbociclib achieved 100% overall response rate (1/3 CR, 2/3 PR)…Taken together, we demonstrated that combining APG-2575 with tamoxifen or palbociclib therapies substantially enhances antitumor activity and overcomes tamoxifen resistance in the preclinical models of ER+ breast cancer, suggesting a novel strategy for the clinical development of BCL-2 inhibitors in ER+ breast cancers.
